In today's point-of-care (POC) market segment, there is an ever-increasing demand for novel and more efficient devices for the early diagnosis of diseases, with a special interest in cancer. According to statistics from the World Health Organization (WHO), each year approximately 7.5 million people around the world die because of this disease. Despite these numbers, the WHO states that most cancer types have high cure rates when detected early and treated according to best practices. Therefore, having early and trustful detection tools for the implementation of preventive mass screening programs is a key factor for reducing cancer mortality rates.

Within this context, appears the SAPHELY project:

Self-amplified photonic biosensing platform for microRNA-based early diagnosis of diseases